Adc Therapeutics SA [NYSE: ADCT] price surged by 2.01 percent to reach at $0.04.
The one-year ADCT stock forecast points to a potential upside of 75.83. The average equity rating for ADCT stock is currently 1.29, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Adc Therapeutics SA [ADCT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADCT shares is $8.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADCT stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stephens have made an estimate for Adc Therapeutics SA shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 08, 2024. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on May 30, 2024, representing the official price target for Adc Therapeutics SA stock. Previously, the target price had yet another raise to $11, while Guggenheim analysts kept a Buy rating on ADCT stock.
The Average True Range (ATR) for Adc Therapeutics SA is set at 0.31, with the Price to Sales ratio for ADCT stock in the period of the last 12 months amounting to 2.78.
ADCT Stock Performance Analysis:
Adc Therapeutics SA [ADCT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.69. With this latest performance, ADCT shares gained by 2.01% in over the last four-week period, additionally sinking by -24.54% over the last 6 months – not to mention a rise of 37.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADCT stock in for the last two-week period is set at 44.89, with the RSI for the last a single of trading hit 44.96, and the three-weeks RSI is set at 44.83 for Adc Therapeutics SA [ADCT]. The present Moving Average for the last 50 days of trading for this stock 2.5800, while it was recorded at 2.0000 for the last single week of trading, and 3.3400 for the last 200 days.
Insight into Adc Therapeutics SA Fundamentals:
Adc Therapeutics SA’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.68 and a Current Ratio set at 4.92.
Adc Therapeutics SA [ADCT] Institutonal Ownership Details
There are presently around $61.60%, or 77.62%% of ADCT stock, in the hands of institutional investors. The top three institutional holders of ADCT stocks are: REDMILE GROUP, LLC with ownership of 15.27 million shares, which is approximately 18.4964%. PROSIGHT MANAGEMENT, LP, holding 9.57 million shares of the stock with an approximate value of $$30.24 million in ADCT stocks shares; and PROSIGHT MANAGEMENT, LP, currently with $$13.64 million in ADCT stock with ownership which is approximately 5.2292%.
